Hence, given the crucial function of the NLRP3 inflammasome in DCM, it may be a viable therapeutic approach to mitigate the likelihood of heart failure in diabetic patients by targeting the NLRP-3 inflammasome pathway [89]. This evidence concerns the gene NLRP3 and familial dilated cardiomyopathy.